United Therapeutics Corpo...

NASDAQ: UTHR · Real-Time Price · USD
298.42
3.82 (1.30%)
At close: May 05, 2025, 3:59 PM
298.70
0.09%
After-hours: May 05, 2025, 07:35 PM EDT
1.30%
Bid 292
Market Cap 13.46B
Revenue (ttm) 2.99B
Net Income (ttm) 1.21B
EPS (ttm) 24.63
PE Ratio (ttm) 12.12
Forward PE 10.12
Analyst Buy
Ask 306
Volume 231,507
Avg. Volume (20D) 518,228
Open 296.61
Previous Close 294.60
Day's Range 293.17 - 299.45
52-Week Range 256.08 - 417.82
Beta 0.63

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 17, 1999
Employees 1,305
Stock Exchange NASDAQ
Ticker Symbol UTHR
Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is $350, which is an increase of 17.28% from the latest price.

Stock Forecasts

Earnings Surprise

United Therapeutics has released their quartely earnings on Apr 30, 2025:
  • Revenue of $794.4M exceeds estimates by $64.58M, with 17.22% YoY growth.
  • EPS of 6.63 exceeds estimates by 0.10, with 7.46% YoY growth.
  • 2 months ago
    -10.8%
    United Therapeutics shares are trading lower after... Unlock content with Pro Subscription
    8 months ago
    +3.04%
    United Therapeutics shares are trading higher after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $400 to $572.